Horizon Therapeutics Public Limited Company (HZNP) BCG Matrix Analysis

If you're interested in investing in pharmaceutical companies, you may have come across Horizon Therapeutics Public Limited Company (HZNP). This blog will provide you with an analysis of Horizon Therapeutics' product portfolio using the Boston Consulting Group Matrix Analysis. By the end of this blog, you will have a better understanding of Horizon Therapeutics' 'Stars,' 'Cash Cows,' 'Dogs,' and 'Question Marks' products and brands.

Horizon Therapeutics Public Limited Company (HZNP) has a diverse range of products and brands. According to the Boston Consulting Group Matrix Analysis, some of these products are flourishing while others are struggling.

• 'Stars' products: High growth, high market share products such as TEPEZZA, Mount Sinai machine learning technology, KRYSTEXXA, and Procysbi.
• 'Cash Cows' products: High market share, low growth products such as KRYSTEXXA, TEPEZZA, and VIMOVO.
• 'Dogs' products: Low market share, low growth products such as Krystexxa, Procysbi, and Ravicti.
• 'Question Marks' products: Low market share, high growth products such as Horizon's treatment for gout and treatment for psoriasis.

It is important to note that Horizon Therapeutics' 'Stars' and 'Cash Cows' products are its largest revenue generators, making them critical to the company's long-term success. On the other hand, 'Dogs' and 'Question Marks' products need a significant investment to turn them around or should be divested to free up resources for better opportunities.

Overall, understanding a company's product portfolio through the Boston Consulting Group Matrix Analysis can be useful for any investor. It provides insight and organization to a complex and diverse product range, allowing investors to make informed decisions.

Background of Horizon Therapeutics Public Limited Company (HZNP)

Horizon Therapeutics Public Limited Company (HZNP) is a biopharmaceutical company headquartered in Dublin, Ireland. The company was founded in 2005 as Horizon Pharma and changed its name to Horizon Therapeutics in 2018. As of 2023, Horizon Therapeutics focuses on the development, production, and commercialization of treatments for patients suffering from rare and rheumatic diseases. The company has a strong portfolio of medications, including Krystexxa, Tepezza, and Procysbi. In 2022, Horizon Therapeutics reported annual revenues of USD 2.4 billion, representing a 15% year-over-year increase. Additionally, the company's net income for the same period was USD 400 million, up from USD 300 million in 2021. Horizon Therapeutics employs over 2,000 people globally and has a market capitalization of over USD 14 billion. Horizon Therapeutics continues to invest in research and development in hopes of expanding its portfolio, improving patient care, and finding new treatments for rare and rheumatic diseases.

• Founded in 2005 as Horizon Pharma, changed name to Horizon Therapeutics in 2018
• Producing medicines for the rare/rheumatic diseases
• Revenues of USD 2.4 billion in 2022; net income of USD 400 million
• Market capitalization of over USD 14 billion
• Employs over 2,000 people globally

Stars	Question Marks
TEPEZZA: medication for Thyroid Eye Disease Mount Sinai machine learning technology: partnership for drug discovery and development KRYSTEXXA: biologic medication for gout Procysbi: medication for Limb-girdle Muscular Dystrophy diseases	Revenue of $2.4 billion in 2021 Treatment for gout with low market share Treatment for psoriasis with low market share
Cash Cow	Dogs
KRYSTEXXA TEPEZZA VIMOVO	Krystexxa - treatment for refractory chronic gout Procysbi - treatment for nephropathic cystinosis Ravicti - medication for urea cycle disorders

Horizon Therapeutics Public Limited Company (HZNP) Stars

As of 2023, Horizon Therapeutics Public Limited Company (HZNP) has established several 'Stars' products/brands according to Boston Consulting Group Matrix Analysis. Among them is TEPEZZA, a medication used to treat Thyroid Eye Disease. TEPEZZA continues to experience high growth with Year over Year (YoY) sales growth of almost 17% and its market share increasing to 19.1%.

• TEPEZZA: A rapidly growing medication used to treat Thyroid Eye Disease. With YoY sales growth of almost 17% and its market share increasing to 19.1%, TEPEZZA is a strong player in the 'Stars' quadrant.
• Mount Sinai machine learning technology: Horizon Therapeutics has partnered with Mount Sinai Health System in the development of advanced machine learning technology to identify new autoimmune disease targets that lead to drug discovery and development.
• KRYSTEXXA: KRYSTEXXA is a biologic medication used to treat gout. The medication continues to experience impressive YoY sales growth of over 16% and its market share increased to 42.4%.
• Procysbi: A medication used to manage a range of Limb-girdle Muscular Dystrophy diseases. Year over Year sales growth for Procysbi continues to rise, reaching almost 13%

It is worth noting that TEPEZZA and KRYSTEXXA are Horizon Therapeutics' largest contributors to revenue, with both products generating $602.6 million and $992.3 million respectively. It is important that Horizon Therapeutics puts in a lot of support for promotion and placement of these products. This is because while these are the leaders in the business, they still require a lot of investment in order to grow into cash cows. If market share is kept and these products are successfully promoted, they are likely to grow into cash cows that generate significant profits for the company.

Overall, for Horizon Therapeutics Public Limited Company (HZNP), it is crucial that the company continues to invest in its 'Stars' products/brands since this is a central tenet of a Boston Consulting Group (BCG) strategy for growth. With high growth products/brands and high market share, these products/brands have the potential to grow into cash cows if maintained effectively.

Horizon Therapeutics Public Limited Company (HZNP) Cash Cows

As of 2023, Horizon Therapeutics Public Limited Company (HZNP) has a few products and/or brands that are considered 'Cash Cows' within the Boston Consulting Group Matrix Analysis. These products have a high market share in a mature market and provide a steady stream of cash flow with high profit margins.

• KRYSTEXXA: KRYSTEXXA is a treatment for Chronic Gout that has shown a consistent demand in the market. As of 2022, KRYSTEXXA generated $310 million in revenue for Horizon Therapeutics.
• TEPEZZA: TEPEZZA is a treatment for Thyroid Eye Disease (TED) and has quickly become a market leader. As of 2022, TEPEZZA generated $1.1 billion in revenue for Horizon Therapeutics.
• VIMOVO: VIMOVO is a treatment for Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. As of 2022, VIMOVO generated $475 million in revenue for Horizon Therapeutics.

These products have a significant share in the relevant market and are not expected to experience significant growth in the near future. Therefore, Horizon Therapeutics is advised to focus on maintaining their current market share and profitability while also investing in supporting infrastructure to improve efficiency and increase cash flow.

Horizon Therapeutics Public Limited Company (HZNP) Dogs

Horizon Therapeutics Public Limited Company (HZNP) has a few products and/or brands that can be classified as dogs in the Boston Consulting Group Matrix Analysis as of 2023. These products have a low market share and low growth rates. As of 2021 and 2022, they have shown minimal financial growth, making them a cash trap for the organization.

• Krystexxa: Krystexxa is a treatment for refractory chronic gout. While it is a unique product in the market, its limited market appeal makes it a dog product for Horizon, with a market share of only 5%. It generated around $72 million in sales in 2021.
• Procysbi: Procysbi is a treatment for a genetic condition called nephropathic cystinosis. Despite being the only FDA-approved treatment for this condition, its limited market and competition from off-label treatments make it a dog product for Horizon, with a market share of only 10%. It generated around $66 million in sales in 2021.
• Ravicti: Ravicti is a medication for urea cycle disorders. Although it is the only FDA-approved medication for this condition, its limited market appeal and competition from off-label treatments make it a dog product for Horizon, with a market share of only 5%. It generated around $187 million in sales in 2021.

For Horizon, these dog products result in revenue generation but take away valuable resources that could be utilized in high growth products. Divestiture or closure of these products could free up resources that could be invested in high growth products, leading to higher returns on investment for the organization.

Horizon Therapeutics Public Limited Company (HZNP) Question Marks

As of 2023, Horizon Therapeutics Public Limited Company (HZNP) has a number of products/brands that fall under the 'Question Marks' quadrant of the Boston Consulting Group Matrix Analysis. These products are in growing markets but have low market share.

• The latest financial information for Horizon Therapeutics Public Limited Company shows that in 2021, the company had a revenue of $2.4 billion.
• One of the products/brands that falls under the 'Question Marks' quadrant as of 2023 is the company's treatment for gout. The market for gout treatments is growing, but the company has a relatively low market share.
• Another product/brand in the 'Question Marks' quadrant is Horizon's treatment for psoriasis. While there is a high demand for psoriasis treatments, Horizon's product has yet to capture a significant market share.

In order to turn these 'Question Marks' into stars, Horizon Therapeutics Public Limited Company needs to focus on increasing the market share of these products quickly. This will require significant investment and marketing efforts.

Horizon Therapeutics Public Limited Company can either invest heavily in these products to gain market share or sell them if they don't have the potential for growth. The company needs to carefully analyze the potential of these products before making any investment decisions.

Horizon Therapeutics Public Limited Company (HZNP) is a pharmaceutical company that has made significant strides in the industry with its high-performing products/brands. Through the use of the Boston Consulting Group Matrix Analysis, we have gained insight into the company's product portfolio and determined which products have the potential to be stars, cash cows, dogs, or question marks.

TEPEZZA and KRYSTEXXA are two of Horizon's standout products/brands that fall under the 'Stars' quadrant. With high growth and a significant market share, these products have the potential to grow into cash cows that generate significant profits for the company, provided that the right investment is made in promotion and placement of the products. Additionally, Horizon has partnered with Mount Sinai Health System in the development of advanced machine learning technology to identify new autoimmune disease targets that lead to drug discovery and development.

• TEPEZZA is a rapidly growing medication used to treat Thyroid Eye Disease.
• KRYSTEXXA is a biologic medication used to treat gout.

VIMOVO, KRYSTEXXA, and TEPEZZA are some of the cash cow products at Horizon. These products have a high market share in a mature market and provide a steady stream of cash flow with high-profit margins. Horizon should focus on maintaining their current market share and profitability while also investing in supporting infrastructure to improve efficiency and increase cash flow.

• VIMOVO is a treatment for Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.

Horizon Therapeutics Public Limited Company also has some products/brands that can be classified as dogs in the Boston Consulting Group Matrix Analysis. These products have a low market share and low growth rates, making them a cash trap for the organization. Horizon should divest or close these products, freeing up resources to invest in high-growth products.

• Krystexxa is a treatment for refractory chronic gout.
• Procysbi is a treatment for a genetic condition called nephropathic cystinosis.
• Ravicti is a medication for urea cycle disorders.

Finally, Horizon has a number of products/brands that fall under the 'Question Marks' quadrant. These products are in growing markets but have low market share. To turn these 'Question Marks' into stars, Horizon needs to focus on increasing their market share quickly, which will require significant investment and marketing efforts. Alternatively, the company can decide to sell these products if they don't have the potential for growth.

• The market for gout treatments is growing, but the company has a relatively low market share.
• Horizon's treatment for psoriasis has yet to capture a significant market share.

As Horizon Therapeutics Public Limited Company continues to develop its products and brands, it is crucial that they identify which ones have the potential for growth and adapt their strategies accordingly. By taking a strategic approach to product management, Horizon can continue to thrive in a constantly evolving industry.